Longeveron Inc. (LGVN)
NASDAQ·Healthcare·Biotechnology
$0.88
-1.77%
Mkt Cap $20.97M
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Mar 17, 2026 | $110.33K | $365.00K | +230.82% | -$0.42 | -$0.22 | +47.62% | — | — |
| Q4 2025 Nov 4, 2025 | $110.33K | $137.00K | +24.17% | -$0.26 | -$0.39 | -50.00% | — | — |
| Q3 2025 Aug 13, 2025 | $444.00K | $316.00K | -28.83% | -$0.35 | -$0.33 | +5.71% | — | — |
| Q2 2025 May 8, 2025 | $592.67K | $381.00K | -35.71% | -$0.34 | -$0.34 | +0.00% | — | — |
| Q1 2025 Feb 28, 2025 | $578.66K | $603.00K | +4.21% | -$0.36 | -$2.50 | -594.44% | — | — |
| Q4 2024 Nov 12, 2024 | $395.50K | $773.00K | +95.45% | -$0.53 | -$0.34 | +35.85% | — | — |
| Q3 2024 Aug 14, 2024 | $500.00K | $468.00K | -6.40% | -$1.03 | -$1.83 | -77.67% | — | — |
| Q2 2024 May 14, 2024 | $60.00K | $548.00K | +813.33% | -$2.01 | -$1.61 | +19.90% | — | — |
| Q1 2024 Feb 27, 2024 | $210.00K | $63.00K | -70.00% | -$2.10 | -$2.50 | -19.05% | — | — |
| Q4 2023 Nov 10, 2023 | $400.00K | $150.00K | -62.50% | -$2.40 | -$2.80 | -16.67% | — | — |
| Q3 2023 Aug 11, 2023 | $400.00K | $217.00K | -45.75% | -$2.60 | -$2.70 | -3.85% | — | — |
| Q2 2023 May 12, 2023 | $300.00K | $279.00K | -7.00% | -$1.90 | -$2.20 | -15.79% | — | — |
| Q1 2023 Mar 10, 2023 | $400.00K | $121.00K | -69.75% | -$1.00 | -$2.10 | -110.00% | — | — |
| Q4 2022 Nov 14, 2022 | $200.00K | $265.00K | +32.50% | -$2.00 | -$2.50 | -25.00% | — | — |
| Q3 2022 Aug 12, 2022 | $200.00K | $466.00K | +133.00% | -$2.30 | -$2.70 | -17.39% | — | — |
| Q2 2022 May 13, 2022 | $250.00K | $370.00K | +48.00% | -$2.10 | -$1.70 | +19.05% | — | — |
| Q1 2022 Mar 11, 2022 | $265.00K | $209.00K | -21.13% | -$2.50 | -$2.00 | +20.00% | — | — |
| Q4 2021 Nov 12, 2021 | — | $232.00K | — | — | -$2.50 | — | — | — |
| Q3 2021 Aug 13, 2021 | — | $489.00K | — | — | -$2.60 | — | — | — |
| Q2 2021 May 14, 2021 | $400.00K | $376.00K | -6.00% | -$0.44 | -$1.80 | -309.09% | — | — |